Latest European Market News

Smart Parking Limited reported a robust half-year result for December 2025, nearly doubling revenue to $62.6 million and boosting adjusted EBITDA by 85%, driven by its US acquisition and international growth.

ECS Botanics has partnered with Nimbus Health to distribute its medicinal cannabis products across Germany, marking its entry into Europe's largest cannabis market. The launch of the OzSun brand is set for April 2026, with premium Terphogz strains to follow later in the year.

EcoGraf Limited has secured a cooperation agreement with the European Investment Bank to advance its vertically integrated battery anode materials projects, reinforcing its role in sustainable critical raw materials supply for the EU.

CSL Limited reported a 7% decline in underlying NPATA to US$1.9 billion for the half-year, weighed down by restructuring costs and impairments, yet maintains full-year guidance and expands its share buy-back program.

Epsilon Healthcare’s subsidiary, Epsilon Pharma, has signed a three-year manufacturing agreement with New Zealand’s Puro to supply medicinal cannabis products to the UK and Europe, marking a significant step in its international expansion.

Heavy Rare Earths Limited has broadened its mineral rights at the Radium Hill project to include all minerals, setting the stage for a maiden drilling campaign in 2026 amid soaring yttrium prices.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.

Little Green Pharma Ltd is set to acquire Cannatrek Ltd in a transformative merger that will create one of the largest vertically integrated medicinal cannabis companies globally, with pro-forma FY25 revenue exceeding AUD 112 million.

Acadia Pharmaceuticals has received a negative vote from the European Medicines Agency’s committee on its application to market trofinetide for Rett syndrome in the EU, prompting plans for a re-examination request.

Evion Group has bolstered its cash reserves to $2.3 million following a strategic placement and secured a $1.5 million expandable graphite sales agreement in the US, while advancing its Maniry Graphite Project in Madagascar with strong EU backing.

International Graphite Limited has secured key approvals and funding to progress its Collie Micronising Facility and European Expandable Graphite Project, positioning itself as a major supplier outside China.